臺灣學術機構典藏系統 (Taiwan Academic Institutional Repository, TAIR)

	English \| 正體中文 \| 简体中文 \| 總筆數 :2875227
	造訪人次 : 54114453 線上人數 : 3457 教育部委託研究計畫計畫執行:國立臺灣大學圖書館

搜尋範圍

進階搜尋

登入

管理

臺灣學術機構典藏系統 (Taiwan Academic Institutional Repository, TAIR)

關於TAIR
	計畫說明

瀏覽
	典藏機構
	作者
	題名
	日期
	統計圖表
	機構即時統計
	學術趨勢

消息
	2019臺灣學術機構典藏研討會
	機構典藏系統RC7版本已發佈

著作權
	出版社及期刊政策查詢
	TAIR著作權會議記錄

相關連結
	機構典藏計畫網站
	ROAR
	OpenDOAR
	SHERPA
	OAIster
	JAIRO
	Ira
	DSPACE
	RWWR
	臺大學術典藏NTU Scholars

"oxnard g r"的相關文件

Return to Browse by Author
Sorting by Title	Sort by Date

Showing items 1-7 of 7 (1 Page(s) Totally)
1
View [10|25|50] records per page

Institution	Date	Title	Author
臺大學術典藏	2021-04-23T05:56:30Z	TATTON: a multi-arm, phase Ib trial of osimertinib combined with selumetinib, savolitinib, or durvalumab in EGFR-mutant lung cancer	Oxnard G.R.;Chih-Hsin Yang;Yu H.;Kim S.-W.;Saka H.;Horn L.;Goto K.;Ohe Y.;Mann H.;Thress K.S.;Frigault M.M.;Vishwanathan K.;Ghiorghiu D.;Ramalingam S.S.;Ahn M.-J.; Oxnard G.R.; CHIH-HSIN YANG; Yu H.; Kim S.-W.; Saka H.; Horn L.; Goto K.; Ohe Y.; Mann H.; Thress K.S.; Frigault M.M.; Vishwanathan K.; Ghiorghiu D.; Ramalingam S.S.; Ahn M.-J.
臺大學術典藏	2020-05-26T09:26:47Z	136O: Osimertinib combined with durvalumab in EGFR-mutant non-small cell lung cancer: Results from the TATTON phase Ib trial	Oxnard G.R.;Walding A;Yang L;Kim S.-W;Goto K;Ramalingam S;Saka H;Yu H;Chih-Hsin Yang;Ahn M.-J; Ahn M.-J; CHIH-HSIN YANG; Yu H; Saka H; Ramalingam S; Goto K; Kim S.-W; Yang L; Walding A; Oxnard G.R.
臺大學術典藏	2020-05-26T09:26:47Z	136O: Osimertinib combined with durvalumab in EGFR-mutant non-small cell lung cancer: Results from the TATTON phase Ib trial	Oxnard G.R.;Walding A;Yang L;Kim S.-W;Goto K;Ramalingam S;Saka H;Yu H;Chih-Hsin Yang;Ahn M.-J; Ahn M.-J; CHIH-HSIN YANG; Yu H; Saka H; Ramalingam S; Goto K; Kim S.-W; Yang L; Walding A; Oxnard G.R.
臺大學術典藏	2020-05-26T09:26:46Z	135O_PR: Plasma genotyping for predicting benefit from osimertinib in patients (pts) with advanced NSCLC	J?nne P.;Chih-Hsin Yang;Barrett C;Cantarini M;Paweletz C.P;Lawrance R;Alden R.S;Thress K.S;Oxnard G.R; Oxnard G.R; Thress K.S; Alden R.S; Lawrance R; Paweletz C.P; Cantarini M; Barrett C; CHIH-HSIN YANG; Jänne P.
臺大學術典藏	2020-05-26T09:26:46Z	135O_PR: Plasma genotyping for predicting benefit from osimertinib in patients (pts) with advanced NSCLC	J?nne P.;Chih-Hsin Yang;Barrett C;Cantarini M;Paweletz C.P;Lawrance R;Alden R.S;Thress K.S;Oxnard G.R; Oxnard G.R; Thress K.S; Alden R.S; Lawrance R; Paweletz C.P; Cantarini M; Barrett C; CHIH-HSIN YANG; Jänne P.
臺大學術典藏	2020-05-26T09:26:44Z	Association between plasma genotyping and outcomes of treatment with osimertinib (AZD9291) in advanced non-small-cell lung cancer	J?nne P.A.;Barrett J.C;Chih-Hsin Yang;Cantarini M;Paweletz C.P;Lawrance R;Alden R.S;Thress K.S;Oxnard G.R; Oxnard G.R; Thress K.S; Alden R.S; Lawrance R; Paweletz C.P; Cantarini M; CHIH-HSIN YANG; Barrett J.C; Jänne P.A.
臺大學術典藏	2020-05-26T09:26:44Z	Association between plasma genotyping and outcomes of treatment with osimertinib (AZD9291) in advanced non-small-cell lung cancer	J?nne P.A.;Barrett J.C;Chih-Hsin Yang;Cantarini M;Paweletz C.P;Lawrance R;Alden R.S;Thress K.S;Oxnard G.R; Oxnard G.R; Thress K.S; Alden R.S; Lawrance R; Paweletz C.P; Cantarini M; CHIH-HSIN YANG; Barrett J.C; Jänne P.A.

Showing items 1-7 of 7 (1 Page(s) Totally)
1
View [10|25|50] records per page